DaVita HealthCare Partners Given “Neutral” Rating at Zacks (DVA)
DaVita HealthCare Partners (NYSE:DVA)‘s stock had its “neutral” rating restated by Zacks in a research report issued to clients and investors on Wednesday, American Banking News.com reports. They currently have a $68.00 target price on the stock. Zacks‘ price objective suggests a potential upside of 5.70% from the stock’s previous close.
Zacks‘ analyst wrote, “DaVita Healthcare posted strong fourth-quarter earnings. Both bottom line as well as top line surpassed the Zacks Consensus Estimate on strong performances in dialysis and related lab services and ancillary services segments. The balance sheet also improved with lower debt and higher shareholder equity. Moreover, higher cash flow, rapidly expanding international presence and an active domestic acquisition strategy are other positives. The merger with HealthCare Partners bodes well for long-term growth. However, the HealthCare Partners segment is expected to be a drag 2014 owing to the MA rate cuts. We retain a Neutral recommendation on DaVita Healthcare.”
DaVita HealthCare Partners (NYSE:DVA) traded up 6.33% on Wednesday, hitting $68.40. 1,200,256 shares of the company’s stock traded hands. DaVita HealthCare Partners has a 1-year low of $52.75 and a 1-year high of $66.76. The stock has a 50-day moving average of $64.33 and a 200-day moving average of $59.20. The company has a market cap of $14.549 billion and a P/E ratio of 23.76.
DaVita HealthCare Partners (NYSE:DVA) last posted its quarterly earnings results on Tuesday, February 11th. The company reported $0.99 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.91 by $0.92. The company had revenue of $3.06 billion for the quarter, compared to the consensus estimate of $2.92 billion. During the same quarter in the prior year, the company posted $1.68 earnings per share. The company’s quarterly revenue was up 23.6% on a year-over-year basis. Analysts expect that DaVita HealthCare Partners will post $3.72 EPS for the current fiscal year.
A number of other firms have also recently commented on DVA. Analysts at Deutsche Bank reiterated a “buy” rating on shares of DaVita HealthCare Partners in a research note on Wednesday. They now have a $72.00 price target on the stock, down previously from $74.00. Separately, analysts at Raymond James upgraded shares of DaVita HealthCare Partners from a “market perform” rating to an “outperform” rating in a research note on Monday, January 6th. Finally, analysts at KeyCorp initiated coverage on shares of DaVita HealthCare Partners in a research note on Tuesday, December 17th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company. DaVita HealthCare Partners has a consensus rating of “Hold” and a consensus price target of $101.33.
DaVita HealthCare Partners Inc, formerly DaVita Inc, is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (NYSE:DVA).
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.